VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, is pleased to announce that its proprietary Hydroxyapatite-coated cardiovascular stent coating technology will be featured in this month's issue of EuroIntervention, an internationally renowned, peer-reviewed scientific journal. This issue is published in conjunction with EuroPCR2006, the Paris course on Re-vascularization, Europe's largest and most important gathering dedicated to cardiovascular intervention.
